開立醫療(300633.SZ)：2020年度由盈轉虧 預虧2932萬元–5732萬元
格隆匯 1 月 29日丨開立醫療(300633.SZ)披露2020年度業績預吿，預計2020年度歸屬於上市公司股東的淨虧損2932.00萬元–5732.00萬元，上年同期盈利1.02億元；扣除非經常性損益後的淨虧損8970.00萬元–1.18億元，上年同期盈利7317.69萬元。2020年度歸屬於上市公司股東的淨利潤與上年同期相比出現虧損，主要原因如下：
(一)計提商譽減值準備
報吿期內，上海威爾遜光電儀器有限公司及上海和一醫療儀器有限公司(以下簡稱威爾遜)2020年經營業績未達預期，根據《會計監管風險提示第8號-商譽減值》及《企業會計準則第8號-資產減值》的相關要求，公司對所有包含商譽的資產組進行初步減值測試後，擬計提商譽減值準備1.96億元–2.1億元。
剔除商譽減值及相關因素影響，2020年公司實現歸屬於上市公司股東的淨利潤預計為1.33億元–1.47億元，較2019年剔除商譽減值後的淨利潤1.22億元有所增長。
公司商譽減值準備實際計提金額需根據評估機構的評估報吿及會計師事務所審計數據確定。
(二)2020年度公司業務情況2020年，公司努力克服新冠疫情對公司經營的負面影響，國內方面，一季度疫情嚴重時期對國內業務影響較大，隨着國內疫情得到控制，公司國內業務逐漸恢復，全年實現國內業務收入的正增長，國內內鏡設備業務仍取得較高增速；國際方面，由於疫情在國外持續蔓延，國際業務未恢復到正常水平，國際業務收入下滑較大。總體來看，受疫情影響，公司全年業務收入有所下滑，但疫情期間因減少出差和展會參與等活動，銷售費用明顯減少，公司彩超產品毛利率水平穩定，內鏡產品毛利率顯著增長，導致整體毛利率有所上升，最終實現剔除商譽減值及相關因素影響後的淨利潤正增長。
(三)非經常性損益影響
報吿期內，非經常性損益對歸屬於母公司淨利潤的影響金額預計為6038.00萬元，為公司取得的政府補助資金、理財產品收益等，上年同期非經常性損益對歸屬於母公司淨利潤的影響金額為2836.00萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
